Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Favezelimab by Merck for Solid Tumor: Likelihood of Approval
Favezelimab is under clinical development by Merck and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...
Favezelimab by Merck for Gastric Cancer: Likelihood of Approval
Favezelimab is under clinical development by Merck and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I...
Risk adjusted net present value: What is the current valuation of Merck's Favezelimab?
Favezelimab is a monoclonal antibody commercialized by Merck, with a leading Phase II program in Primary Mediastinal B-Cell Lymphoma. According...